Table 4.
Overall and lung cancer–specific survival based on presence of idiopathic pulmonary fibrosis
| Entire Cohort |
Received Stage-Appropriate Therapy |
Did Not Receive Stage-Appropriate Therapy |
||||
|---|---|---|---|---|---|---|
| No IPF | IPF | No IPF | IPF | No IPF | IPF | |
| No. of subjects | 53,598 | 855 | 26,358 | 406 | 27,240 | 449 |
| Overall survival | ||||||
| Unadjusted HR (95% CI) | 1 (Ref) | 1.26 (1.17–1.36) | 1 (Ref) | 1.31 (1.17–1.47) | 1 (Ref) | 1.22 (1.11–1.34) |
| Adjusted HR* (95% CI) | 1 (Ref) | 1.35 (1.26–1.45) | 1 (Ref) | 1.46 (1.31–1.64) | 1 (Ref) | 1.29 (1.18–1.43) |
| Lung cancer–specific survival | ||||||
| Unadjusted HR (95% CI) | 1 (Ref) | 1.21 (1.10–1.32) | 1 (Ref) | 1.26 (1.09–1.44) | 1 (Ref) | 1.17 (1.04–1.31) |
| Adjusted HR* (95% CI) | 1 (Ref) | 1.32 (1.21–1.44) | 1 (Ref) | 1.48 (1.29–1.71) | 1 (Ref) | 1.26 (1.12–1.41) |
Definition of abbreviations: CI = confidence interval; HR = hazard ratio; IPF = idiopathic pulmonary fibrosis; Ref = referent.
*
Adjusted for age; sex; marital status; ethnicity; income; Charlson comorbidity index; tumor size, histology, site, and stage; functional status; pulmonary disability; and stage-appropriate therapy.